Aeglea Bio Therapeutics Stock Cash Per Share

Aeglea Bio Therapeutics fundamentals help investors to digest information that contributes to Aeglea Bio's financial success or failures. It also enables traders to predict the movement of Aeglea Stock. The fundamental analysis module provides a way to measure Aeglea Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aeglea Bio stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Aeglea Bio Therapeutics Company Cash Per Share Analysis

Aeglea Bio's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Cash Per Share

 = 

Total Cash

Average Shares

More About Cash Per Share | All Equity Analysis

Current Aeglea Bio Cash Per Share

    
  1.20 X  
Most of Aeglea Bio's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aeglea Bio Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Competition

In accordance with the recently published financial statements, Aeglea Bio Therapeutics has a Cash Per Share of 1.2 times. This is 72.41% lower than that of the Biotechnology sector and 72.29% lower than that of the Health Care industry. The cash per share for all United States stocks is 76.05% higher than that of the company.

Aeglea Cash Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aeglea Bio's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aeglea Bio could also be used in its relative valuation, which is a method of valuing Aeglea Bio by comparing valuation metrics of similar companies.
Aeglea Bio is currently under evaluation in cash per share category among its peers.

Aeglea Fundamentals

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Other Consideration for investing in Aeglea Stock

If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity